Pfizer CEO Blasted By UK Pharma Watchdog

Source: (https://bit.ly/3Vlgrrf)
You might think that an official rebuke of Pfizer's CEO for
misleading the public on the benefits of its COVID vaccine
would be big news, especially given the fill court press by
vaccine absolutists to compel people to receive the shots.
But even with a Google search, I have not yet seen any US
media coverage of a starling rebuke delivered to Pfizer CEO
Dr. Albert Bourla by a panel convened by the UK Prescription
Medicines Code of Practice Authority (PMCPA). The criticism
followed remarks he made in a December 2021 interview with
the BBC. The following account is derived from an article in
the Melbourne, Australia Herald-Sun by Frank Chung.
In early December 2021, Dr Bourla used an interview with BBC
Breakfast to claim that the virus was "thriving" in schools and
"there is no doubt in my mind that the benefits, completely, are
in favour of" giving five-year-olds the vaccine.
"This is disturbing, significantly, the educational system, and
there are kids that will have severe symptoms," he said. (snip)
By March 2022, some data were showing the effectiveness of
the children's vaccine plummeted to just 12 per cent within weeks
of inoculation.
Dr Bourla said in the BBC interview that the main benefit of
immunising children was "the indirect protection of adults".
"The extent to which we can do that and protect adults by avoiding
them being infected by children with the current vaccines is still
quite uncertain," he said.
"So, that's the balance - we clearly want to protect children as much
as possible and we've got good evidence now that this vaccine, even
at a low dose, produces a really good protective immune response
in children and produces many fewer side effects because of the
lower dose.
The CEO's touting of "good evidence" and his promotion of a jab
that turned out to have but 12% effectiveness, drew an almost
immediate complaint:
Shortly after the interview was published, parent lobby group
UsForThem lodged a formal complaint with the Prescription
Medicines Code of Practice Authority (PMCPA).
The complaint alleged Dr Bourla's remarks were "disgracefully
misleading" and "extremely promotional in nature", breaching several
clauses of the Association of the British Pharmaceutical Industry's
(ABPI) code of practice, The Telegraph reported. (snip)
There is simply no evidence that healthy schoolchildren in the UK
are at significant risk from the SARS COV-2 virus and to imply that
they are is disgracefully misleading," the complaint said.
A code of practice panel convened by the PMCPA found Pfizer had
breached the code in a number of different ways, including by
misleading the public, making unsubstantiated claims, and by failing
to present information in a factual and balanced way, according to
The Telegraph.
Pfizer appealed the findings, arguing Dr Bourla's remarks were based
on "up-to-date scientific evidence" and could be substantiated by
the "publicly available independent benefit-risk assessments". 
An appeal board panel met in November, where the breaches relating
to misleading the public, making unsubstantiated claims and the lack
of balance were upheld.
The more serious findings, including that Pfizer had brought
discredit to the industry, had encouraged irrational use of
a medicine and had failed to maintain high standards, were
overturned.
The full case report will be published in coming weeks
(https://bit.ly/3VkveCv).
Pfizer is one of the largest television advertisers in the
United States. That's why I don't expect this strong rebuke
of its CEO to get much publicity here.